End Stage Renal Disease Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on End Stage Renal Disease Market

5.1. COVID-19 Landscape: End Stage Renal Disease Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global End Stage Renal Disease Market, By Treatment

8.1. End Stage Renal Disease Market, by Treatment Type, 2024-2034

8.1.1. Transplant

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Dialysis

8.1.2.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global End Stage Renal Disease Market, Regional Estimates and Trend Forecast

9.1. North America

9.1.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.1.2. U.S.

9.1.2.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.1.3. Rest of North America

9.1.3.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.2. Europe

9.2.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.2.2. UK

9.2.2.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.2.3. Germany

9.2.3.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.2.4. France

9.2.4.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.2.5. Rest of Europe

9.2.5.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.3. APAC

9.3.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.3.2. India

9.3.2.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.3.3. China

9.3.3.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.3.4. Japan

9.3.4.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.3.5. Rest of APAC

9.3.5.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.4. MEA

9.4.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.4.2. GCC

9.4.2.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.4.3. North Africa

9.4.3.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.4.4. South Africa

9.4.4.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.4.5. Rest of MEA

9.4.5.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.5. Latin America

9.5.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.5.2. Brazil

9.5.2.1. Market Revenue and Forecast, by Treatment (2021-2034)

9.5.3. Rest of LATAM

9.5.3.1. Market Revenue and Forecast, by Treatment (2021-2034)

Chapter 10. Company Profiles

10.1. Nipro Corp.

10.1.1. Company Overview

10.1.2. Product Offerings

10.1.3. Financial Performance

10.1.4. Recent Initiatives

10.2. Fresenius Medical Care AG & Co. KGaA

10.2.1. Company Overview

10.2.2. Product Offerings

10.2.3. Financial Performance

10.2.4. Recent Initiatives

10.3. Baxter International, Inc.

10.3.1. Company Overview

10.3.2. Product Offerings

10.3.3. Financial Performance

10.3.4. Recent Initiatives

10.4. Medtronic Plc

10.4.1. Company Overview

10.4.2. Product Offerings

10.4.3. Financial Performance

10.4.4. Recent Initiatives

10.5. B. Braun Melsungen AG

10.5.1. Company Overview

10.5.2. Product Offerings

10.5.3. Financial Performance

10.5.4. Recent Initiatives

10.6. BD

10.6.1. Company Overview

10.6.2. Product Offerings

10.6.3. Financial Performance

10.6.4. Recent Initiatives

10.7. Asahi Kasei Medical Co., Ltd.

10.7.1. Company Overview

10.7.2. Product Offerings

10.7.3. Financial Performance

10.7.4. Recent Initiatives

10.8. Cantel Medical

10.8.1. Company Overview

10.8.2. Product Offerings

10.8.3. Financial Performance

10.8.4. Recent Initiatives

10.9. Nikkiso Co., Ltd.

10.9.1. Company Overview

10.9.2. Product Offerings

10.9.3. Financial Performance

10.9.4. Recent Initiatives

10.10. JMS Co. Ltd.

10.10.1. Company Overview

10.10.2. Product Offerings

10.10.3. Financial Performance

10.10.4. Recent Initiatives

Chapter 11. Research Methodology

11.1. Primary Research

11.2. Secondary Research

11.3. Assumptions

Chapter 12. Appendix

12.1. About Us

12.2. Glossary of Terms